Is testosterone therapy safe for the heart? The best evidence available in 2026 points to cardiovascular neutrality, which is a stronger answer than this therapy had five years ago. The TRAVERSE trial followed more than 5,000 men with preexisting or elevated cardiovascular risk for roughly two years and found no increase in major adverse cardiac events versus placebo and the follow-up TRAVERSE-MID analysis examined coronary plaque volume and reported no significant difference. That is not a blank check. It is a real answer to the question the FDA spent a decade requiring andthe risk that actually shows up in clinical practice is not the heart at all. It is the hematocrit. This article walks through both.
- The TRAVERSE trial found no increase in major adverse cardiac events over roughly two years in high-risk men.
- TRAVERSE-MID found no significant difference in coronary plaque progression.
- The real clinical risk is erythrocytosis, a rising hematocrit andit is fully monitorable.
- Guideline care requires confirmed low morning testosterone on two draws before any prescription.
- Our fee is flat at every dose and the pharmacy bills the medicine separately at cost, so monitoring is never a revenue event.
What the trials actually found
The testosterone and heart question spent years in observational limbo, with studies reporting both directions and the FDA carrying a boxed-warning-level caution pending randomized evidence. TRAVERSE answered the question it was designed to answer. Men with hypogonadism and preexisting or elevated cardiovascular risk were randomized to testosterone gel or placebo andover a median follow-up of about two years the composite of major adverse cardiac events did not differ between groups. A substudy using CT angiography, TRAVERSE-MID, found no significant difference in coronary plaque volume or composition.
Two honest limits sit on that evidence. Two years is a real duration but not a lifetime andthe trial enrolled men with existing or elevated cardiac risk rather than healthy forty-year-olds seeking optimization. What the evidence supports is cardiovascular safety in monitored men with confirmed hypogonadism over trial-scale durations. What it does not support is the marketing leap that testosterone is cardioprotective, which some platforms now imply and no trial has shown.
The risk that actually shows up in practice
Erythrocytosis, a hematocrit that climbs above safe thresholds, is the most common real adverse effect of testosterone therapy. Testosterone stimulates erythropoietin and red cell production andin some patients, especially smokers and men on higher doses, the blood thickens enough to require dose reduction or temporary cessation. The condition is silent until it is not andit is entirely visible on a basic blood count.
This is why the monitoring panel matters more than the starting dose. The Endocrine Society guideline calls for a baseline hematocrit, a recheck during titration and periodic monitoring thereafter, alongside testosterone levels and symptoms. A program that prescribes testosterone without a CBC in its follow-up panel is not monitoring the therapy andthe hematocrit is precisely the kind of risk that quarterly draws catch while they are still just a number on a page.
| Monitoring marker | What it watches | Cadence | ||
|---|---|---|---|---|
| --- | --- | --- | ||
| Total testosterone, morning draw | Whether the dose is therapeutic rather than supraphysiologic | Quarterly during titration | ||
| Hematocrit and CBC | Erythrocytosis, the most common real risk | Quarterly, always | ||
| PSA | Prostate safety, by age and risk | Per guideline, not per marketing | ||
| LH and FSH | The cause of the low testosterone | At diagnosis | ||
| Lipids, HbA1c, hs-CRP, ApoB | The cardiometabolic picture the therapy lives inside | Every 90 days |
Who should not start, stated plainly
Honesty requires naming the exclusions rather than burying them in a consent form. Active prostate cancer is a contraindication andPSA follows age and risk guidelines rather than a clinic's convenience. A personal or family history of certain hormone-sensitive cancers deserves specialist input before starting. Men planning fertility in the near term should have that conversation first, because exogenous testosterone suppresses sperm production and preservation options exist but belong before the first injection, not after. Elevated hematocrit from other causes, untreated severe sleep apnea and uncontrolled heart failure each change the calculus and deserve their own review before therapy begins.
None of these exclusions is exotic. What is unusual is a program that screens for them all at intake rather than discovering them as problems later.


How the fee structure protects the safety conversation
The uncomfortable truth about testosterone therapy in the subscription era is that dose escalation pays the platform andthe hematocrit that should trigger a dose reduction instead becomes an inconvenient finding. Our structure removes that incentive at the root. The membership is one flat $299 per month covering the clinician and four Biomarker Audits a year, with a single $598 first charge covering the first two months together. The medication is billed by the pharmacy at its own price with zero markup, no molecule upcharge and no dose escalation fee, so nobody in our model earns more when the dose climbs. If the hematocrit says reduce, the recommendation is reduce andthe reduction costs our revenue nothing because there was never any revenue attached to the dose.
Who this article is for
The man asking this question is usually either the Stability-Seeking patient who wants therapy done once and done right or the Concierge Longevity Optimizer who wants the risk picture specified rather than hand-waved. Both deserve the same answer. Testosterone therapy for confirmed hypogonadism, prescribed by a named physician after two morning draws and monitored with a quarterly panel that includes the hematocrit and the full cardiometabolic picture, carries a cardiovascular evidence profile that is now genuinely reassuring. The same therapy from a quiz-and-funnel program without labs is a different product wearing the same name andthe difference is the monitoring.
The eligibility check is free, takes a few minutes and never results in a charge unless a clinician accepts you into care.
Frequently Asked Questions
Is testosterone therapy safe for the heart?
The best current evidence points to cardiovascular neutrality. The TRAVERSE trial followed more than 5,000 men with preexisting or elevated cardiovascular risk for about two years and found no increase in major adverse cardiac events versus placebo. Longer-term certainty is still building, which is why monitoring and patient selection matter more than ever.
What is the hematocrit concern with testosterone?
Testosterone stimulates red blood cell production and in some patients hematocrit climbs above safe levels, thickening the blood. This is the most common real safety issue in therapy and it is fully monitorable, which is why hematocrit belongs in every panel and a rising value prompts dose adjustment rather than alarm.
Who should not start testosterone therapy?
Men with active prostate cancer, a history of medullary thyroid concerns related to other therapies, elevated hematocrit from other causes, untreated severe sleep apnea or those planning fertility in the near term without a preservation plan. PSA and a fertility conversation belong in the intake for anyone considering therapy.
Does testosterone therapy raise heart attack risk?
The large trial evidence does not show an increase. Earlier observational studies raised the question and the FDA required the TRAVERSE-type trials to answer it and the answer so far is cardiovascular neutrality in monitored patients. The risk that shows up in practice is hematocrit rather than infarction.
How often should testosterone therapy be monitored?
Testosterone level, hematocrit and symptoms at roughly every 90 days early in therapy, with PSA following age and risk guidelines. Our Biomarker Audit reads the hormone panel together with the full cardiometabolic panel quarterly.
Does the GoodLife Health membership sell testosterone?
No. The fee is one flat $299 per month for the clinician and four Biomarker Audits a year. Any prescription is written to your pharmacy and billed by the pharmacy at its own price with zero markup, so nobody in our model earns more when the dose climbs.
What is the commitment to start?
A single $598 charge covers the first two months together, including the intake and the first Biomarker Audit. It is held at sign-up and charged only once a clinician accepts you into care. From month three it is $299 monthly and you can cancel anytime.
Can I do testosterone therapy through telehealth safely?
Yes, when the protocol is guideline care. Two morning testosterone draws before diagnosis, LH and FSH to characterize the cause, a baseline hematocrit, a named physician licensed in your state and quarterly monitoring. The setting changes nothing about the medicine.
One last thing
The heart question has largely been answered by trials that took a decade and thousands of patients to run. The remaining safety story lives in the blood count and the dose, which is to say in the monitoring. Ask any clinic you are considering what their hematocrit ceiling is and what they do when it is crossed. The programs with an answer are practicing medicine. The programs without one are filling prescriptions.
Related Guides
- Hormone optimization
- Are online TRT clinics legit? What separates care from a funnel
- Can men do hormone optimization without having low testosterone?
- What a Biomarker Audit includes
References
- Lincoff AM et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE), New England Journal of Medicine, 2023. doi.org/10.1056/NEJMoa2302797
- Bhasin S et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline, Journal of Clinical Endocrinology and Metabolism, 2018. doi.org/10.1210/jc.2018-00229
- FDA, testosterone and other anabolic androgenic steroids safety communication. fda.gov